Lantern Pharma (LTRN) Asset Writedowns and Impairment (2022 - 2026)
Lantern Pharma's (LTRN) quarterly Asset Writedowns and Impairment came in at $18727.0 in Q1 2026, down 60.81% YoY from $47789.0 in Q1 2025, and down 56.45% on a QoQ basis from $43002.0 in Q4 2025.
Lantern Pharma (LTRN) Asset Writedowns and Impairment (2022 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 5 years of Asset Writedowns and Impairment data on file, last reported at $18727.0 in Q1 2026.
- Quarterly Asset Writedowns and Impairment fell 60.81% year-over-year to $18727.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $156168.0 (down 13.2% YoY) and the FY2025 annual result came in at $189897.0, up 9.63% from the prior year.
- Asset Writedowns and Impairment retreated to $18727.0 in Q1 2026, from $43002.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $47789.0 in Q1 2025 to a low of $18727.0 in Q1 2026.
- A 5-year average of $39170.5 and a median of $40247.0 in 2023 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2025 — Asset Writedowns and Impairment rose 16.32% — and 2026, when it slumped 60.81%.
- Tracing LTRN's Asset Writedowns and Impairment over 5 years: stood at $36149.0 in 2022, then advanced by 11.6% to $40342.0 in 2023, then increased by 15.64% to $46650.0 in 2024, then retreated by 7.82% to $43002.0 in 2025, then slumped by 56.45% to $18727.0 in 2026.
- The last three Asset Writedowns and Impairment figures came in at $18727.0 (Q1 2026), $43002.0 (Q4 2025), and $47789.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lantern Pharma | 26.05 Mn | 26.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18,727.00 |
| Mar 31, 2026 | 18,727.00 |
| Dec 31, 2025 | 43,002.00 |
| Dec 31, 2025 | 43,002.00 |
| Mar 31, 2025 | 47,789.00 |
| Mar 31, 2025 | 47,789.00 |
| Dec 31, 2024 | 46,650.00 |
| Dec 31, 2024 | 46,650.00 |
| Sep 30, 2024 | 43,469.00 |
| Sep 30, 2024 | 43,469.00 |
| Jun 30, 2024 | 42,008.00 |
| Jun 30, 2024 | 42,008.00 |
| Mar 31, 2024 | 41,084.00 |
| Mar 31, 2024 | 41,084.00 |
| Dec 31, 2023 | 40,342.00 |
| Dec 31, 2023 | 40,342.00 |
| Sep 30, 2023 | 39,614.00 |
| Sep 30, 2023 | 39,614.00 |
| Jun 30, 2023 | 40,247.00 |
| Jun 30, 2023 | 40,247.00 |